SCHEMBL2431811

SCHEMBL2431811

Brc1ccc2nc(-c3ccc(-c4cnco4)cc3)sc2c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 10/20 0.60
GAA P10253 3/20 0.56
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 2/20 0.44
GLA P06280 2/20 0.44
RAB9A P51151 2/20 0.44
NOTUM Q6P988 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
SULT1A1 P50225 1/20 0.41
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ILK Q13418 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2430002 0.90 GAA (0.56) APPGAAMEN1KMT2AMAPT
SCHEMBL2435129 0.84 APP (0.56) APPGAAMAPTKDM4ENPC1
SCHEMBL31120302 0.81 APP (0.81) APPGAAMEN1KMT2AMAPT
SCHEMBL2433296 0.76 KDM4E (0.44) APPGAAMEN1KMT2AMAPT
SCHEMBL2461395 0.76 APP (1.00) APPGAAMEN1KMT2AMAPT
SCHEMBL4157441 0.76 APP (0.72) APPGAAMEN1KMT2AMAPT
SCHEMBL4806067 0.76 APP (0.72) APPGAAMAPTKDM4ENPC1
SCHEMBL14075967 0.76 APP (0.72) APPGAAMEN1KMT2AMAPT
SCHEMBL30903625 0.75 APP (0.71) APPGAAMEN1KMT2AMAPT
SCHEMBL15414023 0.75 APP (0.71) APPGAAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 APP 1/4885GAA 452/4885MEN1 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.